Ninjurin-1 drives atherosclerosis progression via NF-κB/CXCL-8 activation in endothelial cells
Frontiers in Immunology · 2025
DOI: 10.3389/fimmu.2025.1676216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Zhihong Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shaoxing Central Hospital, Shaoxing, China. Hauptthemen laut MEDLINE: Atherosclerosis, NF-kappa B, Interleukin-8, Cell Adhesion Molecules, Neuronal. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Atherosclerosis represents the leading cause of cardiovascular mortality, with persistent inflammation driving residual risk despite lipid-lowering therapies. While Ninjurin-1 (Ninj1) has been implicated in inflammatory diseases, its endothelial-specific role in atherosclerosis remains unclear.
Methods
We conducted integrated molecular, functional, and histological analyses to characterize Ninj1 expression and function in atherosclerosis. Endothelial Ninj1 silencing was performed to assess its effects on NF-κB signaling, CXCL-8 expression, and ox-LDL-induced endothelial dysfunction. In vivo , ApoE-/- mice were treated with the Ninj1 inhibitor mPN12 peptide to evaluate its impact on plaque formation and composition.
Results
Ninj1 silencing in endothelial cells suppressed NF-κB signaling and its key inflammatory mediator CXCL-8, conferring protection against ox-LDL-induced endothelial dysfunction by enhancing proliferation and migration while reducing apoptosis (all p < 0.05). In ApoE -/- mice, pharmacological Ninj1 inhibition with mPN12 peptide significantly attenuated plaque development and lipid accumulation while preserving collagen content.
Discussion
Our results provide the first evidence that endothelial Ninj1 functions as a novel activator of the NF-κB/CXCL-8 axis, establishing its causal role in atherosclerosis and highlighting its potential as a targeted anti-inflammatory therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Shaoxing Central Hospital, Shaoxing, China.
- The Central Affiliated Hospital, Shaoxing University, Shaoxing, China.
- Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Zitieren
APA
Sun, Z., Ma, W., Ye, F., Ren, N., Shen, K., & Dong, N. (2025). Ninjurin-1 drives atherosclerosis progression via NF-κB/CXCL-8 activation in endothelial cells. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1676216
Vancouver
Sun Z, Ma W, Ye F, Ren N, Shen K, Dong N. Ninjurin-1 drives atherosclerosis progression via NF-κB/CXCL-8 activation in endothelial cells. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1676216
BibTeX
@article{Sun2025,
author = {Sun, Zhihong and Ma, Wenjuan and Ye, Feng and Ren, Nana and Shen, Ke and Dong, Nan},
title = {Ninjurin-1 drives atherosclerosis progression via NF-κB/CXCL-8 activation in endothelial cells},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1676216}
}
EUVIMED